Haplotype analysis of the CETP gene:: not TaqIB, but the closely linked-629C→A polymorphism and a novel promoter variant are independently associated with CETP concentration

被引:101
作者
Klerkx, AHEM
Tanck, MWT
Kastelein, JJP
Molhuizen, HOF
Jukema, JW
Zwinderman, AH
Kuivenhoven, JA
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[3] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands
[5] Unilever Res Vlaardingen, Unilever Hlth Inst, Vlaardingen, Netherlands
关键词
D O I
10.1093/hmg/ddg013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The TaqIB polymorphism in intron 1 of the cholesteryl ester transfer protein (CETP) gene is associated with plasma CETP concentration, high-density lipoprotein cholesterol (HDL-C) and coronary artery disease (CAD). These associations are generally thought to arise from linkage disequilibrium between TaqIB and (an)other functional polymorphism(s). To identify putative functional sites, we investigated phenotypic associations of TaqIB and four tightly linked polymorphisms (novel -2708G-->A and +784CCC-->A, and previously identified -971G-->A and -629C-->A) in 709 males with CAD (REGRESS). In addition to genotype analyses, a novel method to estimate haplotype effects was used to examine the individual and joint effects of these DNA variants on CETP concentration and HDL-C. All polymorphisms were associated with CETP concentration and HDL-C, except for -971 with HDL-C. Stepwise regression and haplotype analyses indicated that only -629 was independently associated with HDL-C. Similar analyses additionally indicated that -2708 and -629 were independently associated with CETP concentration, whereby the most frequent alleles acted in a cumulative manner. Nonetheless, detailed haplotype analysis revealed that a 3-polymorphism haplotype model consisting of -2708, -629 and -971 explained the variation in CETP concentration best. The involvement of -971 could be due to interaction effects that were observed between -971 and both -629 (P<0.001) and -2708 (P=0.047). In conclusion, the TaqIB polymorphism is not instrumental in determining CETP or HDL-C levels, but is a marker for the -629 promoter variant. Our analyses, furthermore, indicate that the -2708 and -971 polymorphisms are likely to play a role in determining CETP concentration.
引用
收藏
页码:111 / 123
页数:13
相关论文
共 57 条
[1]  
AKAIKE H, 1973, INT S INFORMATION TH, V2, P267
[2]  
Bernard S, 1998, J LIPID RES, V39, P59
[3]   Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency -: Veterans Affairs HDL Cholesterol Intervention Trial [J].
Brousseau, ME ;
O'Connor, JJ ;
Ordovas, JM ;
Collins, D ;
Otvos, JD ;
Massov, T ;
McNamara, JR ;
Rubins, HB ;
Robins, SJ ;
Schaefer, EJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (07) :1148-1154
[4]   Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport [J].
Bruce, C ;
Chouinard, RA ;
Tall, AR .
ANNUAL REVIEW OF NUTRITION, 1998, 18 :297-330
[5]  
CHANG DJ, 1990, J BIOL CHEM, V265, P9496
[6]  
Corbex M, 2000, GENET EPIDEMIOL, V19, P64, DOI 10.1002/1098-2272(200007)19:1<64::AID-GEPI5>3.0.CO
[7]  
2-E
[8]   Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population [J].
Corella, D ;
Sáiz, C ;
Guillén, M ;
Portolés, O ;
Mulet, F ;
González, JI ;
Ordovás, JM .
ATHEROSCLEROSIS, 2000, 152 (02) :367-376
[9]   New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels - Role of Sp1/Sp3 in transcriptional regulation [J].
Dachet, C ;
Poirier, O ;
Cambien, F ;
Chapman, J ;
Rouis, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) :507-515
[10]   Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study [J].
de Grooth, GJ ;
Kuivenhoven, JA ;
Stalenhoef, AFH ;
de Graaf, J ;
Zwinderman, AH ;
Posma, JL ;
van Tol, A ;
Kastelein, JJP .
CIRCULATION, 2002, 105 (18) :2159-2165